Our healthcare system has built a rigorous process for generating the evidence that clinicians, researchers and pharmaceutical companies rely on. Designing studies, conducting clinical trials, analyzing data, completing regulatory review and publishing results are all essential steps. They are also time consuming. While that rigor should not change, advances in artificial intelligence and modern data science are making it possible to generate high quality real world evidence far more quickly than ever before.
When pharmaceutical companies are evaluating opportunities for new indications or clinicians are caring for a patient with a unique clinical profile, they often rely on the same published literature. Yet the available evidence may not reflect the specific patient, treatment or clinical question at hand. In fact, the majority of day to day clinical decisions are made without direct, high quality evidence that applies to the patient in front of us. One widely cited estimate suggests that 86 percent of clinical questions lack evidence based answers. This is not a failure of clinical judgment. It reflects the limitations of how evidence has traditionally been generated and delivered.
The challenge today is no longer simply finding published literature. Modern AI systems have made literature retrieval and summarization remarkably efficient. The larger challenge is generating new evidence when the literature does not contain the answer. Advances in AI, combined with access to large scale real world clinical data, are beginning to make this possible. Rather than replacing randomized clinical trials, these approaches can rapidly generate observational evidence that evaluates how therapies perform in specific patient populations, particularly those that have historically been understudied.
Integrating Real World Evidence into the Life Science Pipeline
Drug development typically takes eight to twelve years from initial discovery to regulatory approval. Expanding the label of an existing therapy for a new indication, patient population or clinical use often requires many additional years of clinical development and regulatory review.
Generating rigorous real world evidence earlier in the development process has the potential to make that process more efficient. Before investing in large clinical trials, researchers can use observational evidence to better understand which patient populations are most likely to benefit, identify potential safety signals and prioritize the most promising development strategies. Real world evidence does not replace randomized clinical trials or regulatory review. It can substantially accelerate the generation of evidence needed to inform those decisions.
The goal is not to shorten regulatory standards. The goal is to shorten the time required to generate clinically meaningful evidence. By reducing the time between asking an important clinical question and obtaining a reliable answer, AI enabled evidence generation has the potential to reshape how therapies are developed, evaluated, and ultimately delivered to patients.
Resolving Representation Gaps and Fast Tracking Discovery
One of the greatest opportunities for real world evidence is improving our understanding of patient populations that remain underrepresented in traditional clinical trials, including older adults, children, pregnant women, and many racial and ethnic minority populations. Although trial diversity has improved, important evidence gaps remain. Real world evidence can help evaluate treatment effectiveness and safety in these populations while informing future clinical development and, where appropriate, supporting regulatory decisions.
Rapid evidence generation can also enable earlier identification of safety signals and a better understanding of which patients benefit most from particular therapies. Speed alone is not enough. These analyses must still be grounded in rigorous epidemiologic methods, transparent study design and reproducible results. When those principles are maintained, accelerated real world evidence can improve both patient care and drug development.
Opportunities Across the Life Science Value Chain
Beyond label expansion, real world evidence has tremendous potential for drug repositioning. Existing therapies have generated years of clinical experience across millions of patients, creating opportunities to identify treatment effects that may not have been apparent during the original development program. Large scale analyses of real world data can help prioritize promising hypotheses for future clinical investigation.
Rare diseases represent another area where real world evidence can have an outsized impact. Traditional randomized trials are often difficult or impossible because patient populations are small, geographically dispersed, and expensive to enroll. Yet these patients exist within healthcare systems, and their clinical experiences represent valuable sources of evidence. Carefully designed observational studies can provide important insights into treatment effectiveness and safety in settings where randomized trials may never be feasible.
Real world evidence also enables continuous evaluation of therapies after they reach the market, shifting post marketing surveillance from passive reporting toward more proactive, data driven assessment of safety and effectiveness across diverse patient populations.
Reliable Evidence Meets Artificial Intelligence
The value of AI in medicine ultimately depends on the quality of the evidence it can access. A language model can summarize existing knowledge, but if relevant evidence does not exist, it cannot create it on its own. The opportunity is to combine AI with rigorous real world evidence generation so that researchers and clinicians can obtain answers grounded in data from real patients rather than inference alone.
Closing the evidence gap will require trusted systems that combine modern AI with robust epidemiologic methods and high quality real world clinical data. Used responsibly, AI is not a replacement for scientific rigor. It is a powerful tool for accelerating the generation of reliable evidence that can improve drug development and patient care.
Author Bio
